Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma

Miura, John T.; Johnston, Fabian M.; Tsai, Susan; George, Ben; Thomas, Jim; Eastwood, Dan; Banerjee, Anjishnu; Christians, Kathleen K.; Turaga, Kiran K.; Pawlik, Timothy M.; Gamblin, T. Clark

doi:10.1245/s10434-015-4501-8

Cited by 82 publications

(56 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the infiltrative nature of IHC, accounting for the quality of surgical resection is critical in understanding the potential value of adjuvant therapy. In a recent review of patients who underwent surgical resection for IHC in the NCDB, AC was identified as beneficial for patients who had high‐risk features, including positive‐margin resection and lymph node involvement . However, the authors did not separate out radiation therapy, which was received by 49.3% of patients who received AC and by only 4.4% of those who underwent surgery alone.…”

Section: Discussionmentioning

confidence: 99%

The role of surgery and adjuvant therapy in lymph node–positive cancers of the gallbladder and intrahepatic bile ducts

Cao

Zhang

Sada

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The role of surgery and adjuvant therapy in lymph node–positive cancers of the gallbladder and intrahepatic bile ducts

Cao

Zhang

Sada

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…Miura et al. reported the results of adjuvant chemotherapy in 2751 ICC patients, and they analyzed the survival benefit of adjuvant chemotherapy using propensity score‐matched modeling 9. In their series, the propensity score‐matched cohort consisted of 1970 patients (985 patients with surgery alone, and 985 patients with surgery + adjuvant chemotherapy), and adjuvant chemotherapy did not provide a survival benefit in all patients (median OS: 20 vs 23 months, P =.09).…”

Section: Discussionmentioning

confidence: 99%

“…Considerable interest has been paid to various treatment options against ICC recurrence such as surgical treatment,6, 7, 8 chemotherapy,9 radiation therapy,7 radiofrequency ablation (RFA),10, 11 and transarterial chemotherapy 12, 13 with various degrees of success. In recent reports, aggressive surgical treatment for ICC recurrence led to good patient survival after recurrence, with a 3‐year overall survival (OS) rate of 25%,14 40%,6 and 100% 7.…”

Section: Introductionmentioning

confidence: 99%

Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: A multi‐institutional study by the Kyushu Study Group of Liver Surgery

Yamashita

Shirabe²,

Beppu³

et al. 2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Objectives of the present study were to identify predictors of the recurrence of intrahepatic cholangiocarcinoma (ICC), and to evaluate the survival benefit of adjuvant chemotherapy and surgical treatment for ICC recurrence. A multi‐institutional retrospective study was carried out in 356 patients with ICC who underwent curative surgery at one of 14 institutions belonging to the Kyushu Study Group of Liver Surgery. A total of 214 patients (60%) had recurrence. Predictors of ICC recurrence were as follows: positive for pathological intrahepatic metastasis (im), positive for lymph node metastasis (n), positive for pathological lymphatic infiltration (ly), pathological bile duct invasion (b), and tumor size ≥4.4 cm. Adjuvant chemotherapy was given to 120 patients (34%) and, in the patients with im or tumor size ≥4.4 cm, adjuvant chemotherapy showed a survival benefit. Only 37 patients (17%) underwent surgical treatment for ICC recurrence. The surgical treatment resulted in a good 5‐year survival rate (44%), which is similar to the rate obtained by the first operation for primary ICC. Prognosis of patients with primary im after the second operation was significantly worse (5‐year survival 18%) compared to patients without primary im. Primary im+ should be considered a contraindication for surgical treatment for ICC recurrence.

show abstract

“…CCA usually metastasize and cause relapse because it is commonly diagnosed in the advanced stage of the disease, and leads to poor prognosis [2][3][4]. Many studies have revealed that numerous genes are involved in CCA [5][6][7][8][9] and many therapeutic strategies have been developed to treat CCA [10][11][12]; however, the survival rate for CCA patients is still low [13]. In this case, the pathogenesis and progression of this malignancy remains to be investigated and new therapeutic targets need to be explored.…”

Section: Introductionmentioning

confidence: 99%

miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma

Kang

Leng

Liu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Cholangiocarcinoma (CCA) is one of the most common malignant tumors of the biliary tract originating from biliary epithelial cells. Although many therapeutic strategies have been developed to treat CCA, the survival rate for CCA patients is still quite low. Thus it is urgent to elucidate the pathogenesis of CCA and to explore novel therapeutic targets. miR-191 has been shown to be associated with many human solid cancers, but the function of miR-191 in CCA is still poorly understood. Methods: We first investigated the expression level of miR-191 in human CCA tissues and cell lines with quantitative real-time PCR (qRT-PCR). The effects of miR-191 on CCA cells were determined by Cell Counting Kit-8 assay, colony formation assay and acridine orange/ethidium bromide staining. Finally, we utilized qRT-PCR, western blot and luciferase reporter assays to verify the miR-191 target gene. Results: We showed that miR-191 was up-regulated in CCA cell lines and patients. Knockdown of miR-191 by transfection of its inhibitor sequence blocked RBE cells viability and induced apoptosis of RBE cells. Both qRT-PCR and western blot analysis showed that the secreted frizzled-related protein-1 (sFRP1) level was negatively correlated with that of miR-191. Luciferase assay validated that sFRP1 was a direct target of miR-191. Moreover, knockdown of miR-191 led to suppression of Wnt/β-catenin signaling activation. Co-transfection of sFRP1 small interfering RNA (siRNA) and miR-191 inhibitor re-activated the Wnt/β-catenin signaling pathway as detected by an increased level of β-catenin and phosphorylation of GSK-3β, and restored the expression of survivin and c-myc in RBE cells. Co-transfection of sFRP1 siRNA with miR-191 inhibitor restored the colony formation ability and viability of RBE cells. Conclusion: Taken together, our results demonstrate a novel insight into miR-191 biological function in CCA. Our findings suggest that miR-191 is a potential therapeutic target of CCA treatment.

show abstract

Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma

Abstract: The use of chemotherapy was associated with a survival benefit only for ICC patients with nodal metastasis, advanced tumor stage, or an inadequate surgical resection. Chemotherapy for resected ICC should be strongly considered for tumors harboring high-risk features.

Cited by 82 publications

References 17 publications

The role of surgery and adjuvant therapy in lymph node–positive cancers of the gallbladder and intrahepatic bile ducts

The role of surgery and adjuvant therapy in lymph node–positive cancers of the gallbladder and intrahepatic bile ducts

Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: A multi‐institutional study by the Kyushu Study Group of Liver Surgery

miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma

Contact Info

Product

Resources

About